REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.72
Bid: 18.72
Ask: 18.98
Change: 0.04 (0.21%)
Spread: 0.26 (1.389%)
Open: 18.72
High: 18.72
Low: 18.72
Prev. Close: 18.81
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

8 Aug 2023 07:00

RNS Number : 5721I
Nanoco Group PLC
08 August 2023
 

For Immediate Release 8 August 2023

 

NANOCO GROUP PLC

("Nanoco", the "Company" or the "Group")

 

Year End Trading Update

 

Transitioning from an R&D first mover to a commercial producer of scale

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, today provides the following year end trading update ahead of the announcement of its final results for the year to 31 July 2023, which will be released in October 2023.

Overview

· Nanoco is now closer to commercial production than at any time in its 20-year history

· Nanoco is in the strongest financial position since its inception

· Nanoco's core markets of sensing and display are forecast to experience rapid growth

· Nanoco is leveraging its Samsung litigation experience to generate further value from its IP

Operational highlights for the year

· Significant progress with our two global electronics supply chain customers:

European electronics customer: major work package completed as planned by Nanoco in April 2023 for two materials now in final validation - awaiting final response from customer

Major Asian chemical customer: fifth short term work package underway having successfully delivered all technical milestones in four others during FY23 / FY22

Ongoing discussions with both major customers on longer and deeper collaborations

European and Asian customers above have reach into thousands of their own customers

· Successfully completed consolidation of all operations into the Group's Runcorn production site

· Expansion of workforce and organic investment in preparation for a commercial production order expected bythe end of CY23

· Nanoco and advisers actively working to pursue potential infringers of the Group's IP

· Completed capital reduction to facilitate return of up to £40m to shareholders in early 2024

Financial highlights

· Unaudited revenues of £5.6m more than double FY22 and in line with the Board's expectations

· Underlying adjusted EBITDA also remains in line with the Board's expectations

· The expected impact of the litigation settlement on the Group's income statement remains in line with the disclosures set out in Note 7 to the Interim Results for the six months ended 31 January 2023 and is still subject to statutory audit, detailed tax calculations and changes in exchange rates

· Payment and use of proceeds from the litigation settlement:

First tranche of £62.1m received in March 2023 with majority used to pay funder and advisors

Second $75.0m tranche due by 3 February 2024 will be wholly for Nanoco (less $3.25m Korean withholding tax)

· Unaudited cash position at 31 July 2023 of £8.2m, an increase of £2.2m since 31 January 2023

· Gross fixed cash cost base c.£0.5m per month before revenue, other operating income and tax impacts - an increase of just over £0.1m per month following investment in new staff capacity and inflationary cost increases in H2 FY23

Notice of final results

The Company expects to announce its final results for the year ended 31 July 2023 in the second half of October 2023.

Brian Tenner, Chief Executive of Nanoco, said:

"Over the last year we have made significant progress, taking Nanoco to its current inflection point. Consistent feedback from the European customer supports the expectation of commercial production by the end of this calendar year. This transition from an R&D first mover to a commercial producer of scale is underpinned by the litigation proceeds and our validated IP for which we are actively pursuing further monetisation opportunities."

 

Dr Christopher Richards, Non-Executive Chairman of Nanoco, said:

"Nanoco's experienced Board are firmly focused on delivering value for all shareholders. The litigation proceeds allow us to drive the organic business forward while underpinning our firm commitment to return up to £40m of cash to shareholders in early 2024. In addition to last year's commercial progress, we committed to assess the option to appoint a further Non-Executive Director to the Board, based on business needs. A search process for a new independent Non-Executive Director with strong electronics sector commercial experience is well underway."

 

- Ends -

For further information, please contact:

Nanoco Group PLC:

Brian Tenner, CEO +44 (0) 161 603 7900

Liam Gray, CFO & Company Secretary +44 (0) 161 603 7900

 

Peel Hunt (Joint Corporate Broker):

Paul Gillam +44 (0) 20 7418 8900

Richard Chambers

James Smith

 

Turner Pope Investments (Joint Corporate Broker):

Andrew Thacker +44 (0) 20 3657 0050

James Pope

 

MHP Communications: +44 (0) 203 128 8570

Reg Hoare

Pete Lambie

nanoco@mhpc.com

 

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots and other nano-materials. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display, Sensor and Electronics markets. An interesting property of quantum dots is their absorption spectrum. Nanoco's HEATWAVE™ quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including image sensors. Another interesting property of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPRMMTMTJMTRJ
Date   Source Headline
1st Aug 20237:13 amRNSTotal Voting Rights
28th Jul 20235:23 pmRNSDirector/PDMR Shareholding
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.